Shares of Biocon Limited are likely to remain in focus after the biopharmaceutical major reported a significant turnaround in its Q2FY26 results, swinging to a profit on the back of improved margins and robust revenue growth.
The company posted a consolidated net profit of ₹84.5 crore for the quarter ended September 30, 2025, compared to a loss of ₹16 crore in the same period last year. The performance was driven by higher contributions from key business segments and improved operational efficiency.
Strong Growth Across Financial Metrics
Biocon’s operating revenue rose 20% year-on-year (YoY) to ₹4,296 crore, while consolidated revenue grew 21% to ₹4,389 crore.
The company’s EBITDA increased 29% YoY to ₹928 crore, with margins improving to 21%, indicating better cost management and productivity.
Core EBITDA grew 23% to ₹1,218 crore, reflecting a 28% margin, while profit before tax (before exceptional items) surged 153% YoY to ₹183 crore, showcasing broad-based financial recovery.
Continued R&D Investment
Biocon maintained its focus on innovation, with net research and development (R&D) spending at ₹251 crore, representing 7% of revenue (excluding Syngene). The sustained R&D investments underline the company’s commitment to expanding its biosimilars and generics portfolio in global markets.
Segmental Performance Highlights
- Biosimilars: Revenue rose 25% YoY to ₹2,721 crore, continuing to be Biocon’s largest business vertical.
- Generics: Posted ₹774 crore, up 24% YoY, supported by stable demand and new product launches.
- CRDMO (Syngene): Recorded ₹911 crore, marking a 2% YoY increase amid steady performance.
For the quarter, Biosimilars contributed 61% of total revenue, followed by CRDMO at 21% and Generics at 18%.
Summary
Biocon’s Q2FY26 performance reflects a robust financial rebound, driven by double-digit growth across all major business segments and margin expansion. With rising global demand for biosimilars and steady traction in generics, the company appears well-positioned to sustain growth momentum in the coming quarters, supported by continued R&D investments and operational efficiency improvements.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.